Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)
Clinical trial NCT00812019 · COMPLETED
Trial details
- NCT number
- NCT00812019
- Sponsor
- Seqirus
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2008-11-01
- Primary completion
- 2009-03-01
- Enrollment
- 753
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.